FR3108031B1 - Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes - Google Patents

Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes Download PDF

Info

Publication number
FR3108031B1
FR3108031B1 FR2002475A FR2002475A FR3108031B1 FR 3108031 B1 FR3108031 B1 FR 3108031B1 FR 2002475 A FR2002475 A FR 2002475A FR 2002475 A FR2002475 A FR 2002475A FR 3108031 B1 FR3108031 B1 FR 3108031B1
Authority
FR
France
Prior art keywords
back pain
prevention
treatment
nmn
corresponding compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2002475A
Other languages
English (en)
Other versions
FR3108031A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2002475A priority Critical patent/FR3108031B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to JP2022555073A priority patent/JP2023518206A/ja
Priority to CA3175088A priority patent/CA3175088A1/fr
Priority to AU2021236358A priority patent/AU2021236358A1/en
Priority to US17/910,581 priority patent/US20230172959A1/en
Priority to EP21710972.7A priority patent/EP4117676A1/fr
Priority to CN202180032248.4A priority patent/CN115484962A/zh
Priority to PCT/EP2021/056318 priority patent/WO2021180915A1/fr
Publication of FR3108031A1 publication Critical patent/FR3108031A1/fr
Application granted granted Critical
Publication of FR3108031B1 publication Critical patent/FR3108031B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables, pour son utilisation dans la prévention et/ou le traitement d’une douleur dorsale telle qu’une lombalgie, une dorsalgie ou une cervicalgie, de préférence une lombalgie chronique, ainsi que les compositions le comprenant.
FR2002475A 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes Active FR3108031B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2002475A FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
CA3175088A CA3175088A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucleotide ou de certains de ses derives pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
AU2021236358A AU2021236358A1 (en) 2020-03-12 2021-03-12 Use of a nicotinamide mononucleotide or some of its derivatives for preventing and/or treating dorsal pain, and corresponding compositions
US17/910,581 US20230172959A1 (en) 2020-03-12 2021-03-12 Use of nmn for the prevention and/or treatment of a back pain and corresponding compositions
JP2022555073A JP2023518206A (ja) 2020-03-12 2021-03-12 背部痛を予防および／または治療するためのニコチンアミドモノヌクレオチドまたはその誘導体のいくつかの使用、ならびに対応する組成物
EP21710972.7A EP4117676A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
CN202180032248.4A CN115484962A (zh) 2020-03-12 2021-03-12 烟酰胺单核苷酸或其某些衍生物用于预防和/或治疗腰背颈部疼痛的用途，以及相应的组合物
PCT/EP2021/056318 WO2021180915A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002475 2020-03-12
FR2002475A FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes

Publications (2)

Publication Number Publication Date
FR3108031A1 FR3108031A1 (fr) 2021-09-17
FR3108031B1 true FR3108031B1 (fr) 2024-02-16

Family

ID=71661990

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2002475A Active FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes

Country Status (8)

Country Link
US (1) US20230172959A1 (fr)
EP (1) EP4117676A1 (fr)
JP (1) JP2023518206A (fr)
CN (1) CN115484962A (fr)
AU (1) AU2021236358A1 (fr)
CA (1) CA3175088A1 (fr)
FR (1) FR3108031B1 (fr)
WO (1) WO2021180915A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US8690857B2 (en) * 2010-07-23 2014-04-08 Aleeva Medical Inc. Alleviate back pain with lactic acid inhibitors
MX2016016071A (es) * 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
US10603334B2 (en) * 2015-04-28 2020-03-31 NewSouth Innovation Pty. Limited Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
DK3331894T3 (da) 2015-08-05 2021-03-22 Metro Int Biotech Llc Nicotinamidmononukleotidderivater og anvendelser deraf
WO2017079195A1 (fr) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside et dérivés de nicotinamide mononucléotidique utiles dans les traitements de maladies associées aux mitochondries
US20170165282A1 (en) * 2015-12-11 2017-06-15 Bontac Bio-Engineering (Shenzhen) Co., Ltd. Use of beta-nicotinamide mononucleotide in preparation of drugs for preventing and treating arteriosclerosis and cardio-cerebrovascular diseases, and drugs containing the same
CN107233352A (zh) * 2017-06-20 2017-10-10 同济大学 烟酰胺腺嘌呤二核苷酸在制备治疗炎性痛药物中的应用
FR3106056B1 (fr) * 2020-01-13 2021-12-17 Nuvamid Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes

Also Published As

Publication number Publication date
JP2023518206A (ja) 2023-04-28
EP4117676A1 (fr) 2023-01-18
FR3108031A1 (fr) 2021-09-17
AU2021236358A1 (en) 2022-10-06
WO2021180915A1 (fr) 2021-09-16
CA3175088A1 (fr) 2021-09-16
CN115484962A (zh) 2022-12-16
US20230172959A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX2020012595A (es) Composiciones farmaceuticas topicas.
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
FR3106056B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
MA34474B1 (fr) Agonistes de gpr40
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA34045B1 (fr) Ligands sigma destinés à être utilisés pour la prévention et/ou le traitement de la douleur postopératoire
MA32785B1 (fr) Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine
PH12019502330A1 (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
Pinto et al. Martorell's ulcer: diagnostic and therapeutic challenge
BR112022015151A2 (pt) Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
FR3108032B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
FR3108031B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
FR3100449B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210917

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5